Fu-peng Liu et al. Journal of Diabetes. Doi: 10.1111/1753-0407.12200
There are now a number of studies which have compared treatment of type 2 diabetes with the once daily basal analogue insulin glargine versus a Glucagon-like Peptide-1 receptor agonist (GLP-1RA) agent. The outcomes have been consistent with the GLP-1RAs achieving significantly better reductions in HbA1c, however, the studies have been criticised by several authors on the basis that the insulin titration regimes have been inadequate.